Skip to main content

Advertisement

Table 2 Studies included in the systematic review

From: A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas

MicroRNA Cancer type Biofluid type Deregulation Author Reference
miR-125b Bladder cancer Urine ↓ tumors vs controls Zhang et al. 46
↓ high-grades vs low-grades
Uveal Melanoma Plasma ↑tumors vs controls Achberger et al. 47
Advanced Melanoma Seruma ↓tumors vs controls Alegre et al. 48
Ewing’s sarcoma Serum ↓ tumors vs controls Nie et al. 49
Breast cancer Serum ↑ late stages vs controls Wang et al. 50
↑ late stages vs early stages
Breast cancer Urine ↓ tumors vs controls Erbes et al. 51
Breast cancer Serum ↑ tumors vs controls Mar-Aguilar et al. 52
Breast cancer Serum ↑ tumors vs controls Matamala et al. 53
Non-small-cell lung cancer Serum ↑ tumorsvs controls Yuxia et al. 54
↑ late stages vs early stages
Non-small-cell lung cancer Plasma ↑ tumors vs controls Zhao et al. 55
↑ late stages vs early stages
Diffuse large B-cell lymphoma Serum ↑ tumors vs controls Yuan et al. 56
Laryngeal squamous cell carcinoma Plasma ↓ tumors vs controls Ayaz et al. 57
Glioma Serum ↓ tumors vs controls Wei et al. 32
↓ high-grades vs low-grades
Colorectal neoplasia Serum ↑ tumors vs controls Yamada et al. 58
miR-497 Bladder cancer Plasma ↓ tumors vs controls Du et al. 59
Astrocytoma Serum ↓ tumors vs controls Yang et al. 26
Nasopharyngeal carcinoma Plasma ↓ tumors vs controls Wang et al. 60
Prostate cancer Serum ↓ tumors vs controls Kong et al. 61
Cervical cancer Serum ↑ tumors vs controls Zhang et al. 62
  1. aExosomal fraction only